This phenomenon is best described in the EGFR-mutant NSCLC subtype [4, 649], but has been progressively noticed in NSCLC with other driver mutations such as ALK, KRAS, and RET [650–652]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.